Kornimate/medical-research-clean huggingface dataset:
prediction model of icis combined with chemotherapy in advanced nsclc

Conditions: Lung Cancer, Nonsmall Cell

Summary: the reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. this study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ici) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.


Eligibility criteria:
inclusion criteria: 1. male and female, ≥18 years old; 2. patients with a definite cytological or histopathological diagnosis of non-small cell lung cancer; 3. locally advanced (stage iiib/iiic) or metastatic (stage iv) nsclc unable to receive radical surgery and/or radical radiotherapy (with or without concurrent chemotherapy) (ajcc cancer stage 8 clinical stage) 4. there is no known alk gene translocation 5. for patients with egfr-negative non-squamous cell carcinoma, or patients with egfr-negative/unknown squamous cell carcinoma, it is required that they have not received systemic antitumor therapy for advanced nsclc in the past (patients have received neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy or chemoradiotherapy for curing non-metastatic disease in the past, a disease-free interval of ≥6 months was required between the last chemotherapy and/or radiotherapy). 6. patients with non-squamous cell carcinoma with egfr-sensitive mutation and egfr tki progression could be enrolled if they met any of the following requirements: progress in treatment of 1/2 generation egfr tki, t790m-; egfr tki treatment progress of 1/2 generation, t790m+, after 3 generations of egfr tki treatment progress again; t790m status was not considered in patients who had progressed to the initial 3 generations of egfr tki therapy. 7. at least 1 measurable lesion according to recist 1.1 8. receiving immune checkpoint inhibitor therapy for more than 2 cycles 9. ecog ps 0-1 score 10. be able to understand and abide by the requirements of the agreement, and voluntarily participate in the study. exclusion criteria: 1. patients participating in other clinical studies; 2. patients with serious lack of diagnosis and treatment data; 3. patients could not understand the purpose of the study or disagreed with the requirements of the study; 4. a history of other tumors within 5 years; 5. patients judged by the researchers as not suitable for inclusion in this study
hope intervention for covid-19

Conditions: COVID-19 Vaccination

Summary: the harnessing online peer education covid-19 (hope covid-19) intervention will assess whether a peer-led online support community can improve behavioral health outcomes related to covid-19.

the harnessing online peer education covid-19 (hope covid-19) intervention will assess whether a peer-led online support community can improve behavioral health outcomes related to covid-19. participants in the intervention group will be assigned to peer leaders trained in the hope intervention methods.

Eligibility criteria:
inclusion criteria: 1. 18-30 years old 2. english speakers only 3. u.s. resident 4. part of phase 1a or 1b of covid-19 vaccine rollout (healthcare personnel, education, and frontline essential workers, verified through linkedin profile) 5. uses social media and/or online communities greater than twice per week 6. has, or is willing to accept a friend request and group invite from our facebook social media page 7. have not received a covid-19 vaccine and do not have medical conditions or other circumstances preventing them from receiving one exclusion criteria: -
clinico-biological collection to investigate the physiopathology of systemic autoimmune diseases

Conditions: Lupus Erythematosus; Scleroderma; Myositis; Vasculitis; Inflammatory Bowel Diseases

Summary: the aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. this collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies

autoimmune diseases group together less than a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (fai²r: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). the common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. in addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. consequently and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.

Eligibility criteria:
inclusion criteria: * patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example), * patients with atypical presentations of documented or probable systemic autoimmune diseases, * patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.). exclusion criteria: * known anemia and hemoglobin \<10 g / dl * patients under protective supervision (guardianship, curators) * pregnant or breastfeeding woman

Keywords: systemic autoimmune diseases scleroderma lupus myositis vasculitis inflammatory bowel diseases new therapies
motivational counseling in preventing smoking relapse after pregnancy in pregnant women who quit smoking during pregnancy

Conditions: Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder

Summary: rationale: motivational counseling may help prevent pregnant women from smoking again after pregnancy. purpose: this randomized clinical trial is studying three different types of counseling to see how well they work in preventing smoking relapse after pregnancy in pregnant women who quit smoking during pregnancy.

objectives: * develop and evaluate 2 "motivational relapse prevention" (mrp) treatments of varying intensity for reducing postpartum smoking relapse among pregnant women who quit smoking during pregnancy. * assess mrp and enhanced mrp (mrp+) effects on treatment mechanisms and the role of those mechanisms in mediating mrp and mrp+ effects on abstinence. * assess the cost-effectiveness of both the mrp and mrp+ treatments relative to each other and to usual care for reducing postpartum smoking relapse. outline: this is a randomized study. participants are randomized to 1 of 3 intervention arms. * arm i (usual care \[uc\]): participants receive self-help materials and brief relapse prevention advice based on the treating tobacco use and dependence clinical practice guideline. * arm ii (motivational relapse prevention \[mrp\]): participants receive the same intervention as in arm i. participants also undergo telephone counseling over 30 minutes at 34 and 36 weeks gestation and then at 2, 4, 7, and 16 weeks postpartum. * arm iii (enhanced mrp \[mrp+\]): participants receive the same intervention as in arm i and telephone counseling as in arm ii. participants also undergo in-person counseling over 1 hour at 30-33 weeks gestation and then at 8 weeks postpartum. participants in all arms complete questionnaires at baseline, at 30-33 weeks gestation, and then at 8 and 26 weeks postpartum. participants are followed at 8 and 26 weeks postpartum. projected accrual: a total of 450 participants will be accrued for this study.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. former smoker who quit during pregnancy as assessed via self-report 3. smoked an average of greater than or equal to 1 cigarette per day during the year prior to the current pregnancy 4. gestational age \< 33 weeks and ability to attend an in-person visit at university of texas md anderson cancer center (utmdacc) between 30-33 weeks of gestational age 5. can speak, read and write in english. 6. must have a functioning home or personal cell phone exclusion criteria: 1) high-risk pregnancy or known negative birth outcome

Keywords: non-small cell lung cancer small cell lung cancer bladder cancer cervical cancer esophageal cancer gastric cancer renal cell carcinoma adult primary liver cancer pancreatic cancer hypopharyngeal cancer lip and oral cavity cancer laryngeal cancer nasopharyngeal cancer oropharyngeal cancer paranasal sinus and nasal cavity cancer adult acute myeloid leukemia tobacco use disorder
telesupport: evaluation of professionally led support groups for caregivers

Conditions: Caregiver Burden

Summary: this study is a collaborative effort between a community-based service organization, supportive older women's network (sown), and an academic research division at thomas jefferson university (tju). we plan to use a randomized controlled two-group design to: 1) test the effectiveness of the intervention at 6 months to enhance social support and perceived efficacy in comparison to a control group; 2) test if gains are sustained over 12 months (within experimental group comparison); and 3) evaluate the cost and cost effectiveness of the intervention. three secondary study aims are to describe the process and content of tele-support groups (dose/intensity, support group topics); evaluate the relative benefits for african american and white females; and determine if control group subjects benefit from receiving a peer's telephone number for mutual support (within group comparison between 6 and 12 months).


Eligibility criteria:
inclusion criteria: * caregivers will be recruited for study participation who fit the following criteria: 1) female, 2) 55 or older, 3) has been a caregiver for a minimum of 6 months, 3) provides care to a person with a physician's diagnosis of adrd, 4) has weekly access to a telephone for one hour without interruption during working hours, or if unable to have uninterrupted time, willing to have home-maker service. homemaker service during the tele-group meetings will be arranged by the recruitment source. for this study, we plan to recruit only females since they represent the majority of those providing care to persons with adrd and have been shown to demonstrate significantly more stress and negative health outcomes than male caregivers. exclusion criteria: * male * under age of 55 * not a caregiver of person with adrd

Keywords: support groups alzheimer's disease
identification of the udi-6 and the iiq-7 cutoff scores in urinary incontinent women

Conditions: Quality of Life; Urinary Incontinence,Stress; Urinary Incontinence

Summary: purpose urogenital distress inventory-6 (udi-6), incontinence impact questionnaire-7 (iiq-7) and the international consultation on incontinence (iciq-sf) short form are used to diagnose individuals with urinary incontinence (ui) and to assess the impact of the dysfunction on patient quality of life. while iciq-sf has fixed cutoff values - udi-6 and iiq-7 do not. we aimed to find the cutoff scores for udi-6 and iiq-7 in women with ui. methods the study involved 205 women aged between 31 and 83 years - 155 with, and 50 without ui symptoms. all participants completed all three questionnaires: iciq-sf, udi-6 and iiq-7. patients were categorized according to their iciq-sf scores, as symptomatic iciq-sf ≥6 (n=134) and asymptomatic iciq \< 6 (n=60). the receiver operating characteristics (roc) curve was used to test how well udi-6 allowed a discrimination between patients suffering from ui and those who do not. auc (area under curve) statistic was calculated to measure the udi-6 and iiq-7 total score efficiency.

purpose urogenital distress inventory-6 (udi-6), incontinence impact questionnaire-7 (iiq-7) and the international consultation on incontinence (iciq-sf) short form are used to diagnose individuals with urinary incontinence (ui) and to assess the impact of the dysfunction on patient quality of life. while iciq-sf has fixed cutoff values - udi-6 and iiq-7 do not. we aimed to find the cutoff scores for udi-6 and iiq-7 in women with ui. methods the study involved 205 women aged between 31 and 83 years - 155 with, and 50 without ui symptoms. all participants completed all three questionnaires: iciq-sf, udi-6 and iiq-7. patients were categorized according to their iciq-sf scores, as symptomatic iciq-sf ≥6 (n=134) and asymptomatic iciq \< 6 (n=60). the receiver operating characteristics (roc) curve was used to test how well udi-6 allowed a discrimination between patients suffering from ui and those who do not. auc (area under curve) statistic was calculated to measure the udi-6 and iiq-7 total score efficiency.

Eligibility criteria:
inclusion criteria: * ui symptoms exclusion criteria: * lack of consent, oncological diseases

Keywords: incontinence impact questionnaire-7 urogenital distress inventory-6
reduced-pressure pneumoperitoneum and intraperitoneal saline washout to alleviate pain following vnotes hysterectomy

Conditions: Pain, Inflammatory; Pain Management

Summary: vnotes, initially employed for cholecystectomy, appendectomy, and nephrectomy, made its debut in the field of gynecologic surgery in 2012. the advantages of vnotes-such as minimized postoperative discomfort, quicker recovery, and superior cosmetic results-combined with gynecologists' familiarity with the vaginal approach, have contributed to the swift global adoption of vnotes in gynecological procedures. preliminary trials have demonstrated its safety and practicality. although laparoscopy plays a crucial role in surgical procedures, post-operative pain remains a major concern linked to this minimally invasive technique, despite being less intense than the pain from a laparotomy. visceral pain after laparoscopy can stem from the stretching of the peritoneum and diaphragm caused by pneumoperitoneum, as well as from inflammatory cytokines released due to blood accumulation in the abdominal cavity. this pain is typically described as a dull, widespread ache found in the abdominal or thoracic region and often extends to the shoulders. it corresponds to a rise in painkiller use aligned with enhanced recovery after surgery strategies for both preoperative and postoperative stages. moreover, the trendelenburg position could intensify shoulder pain due to increased diaphragm irritation from pneumoperitoneum. effective pain management promotes early movement, lowering the risk of blood clots and decreasing lung complications like atelectasis or pneumonia. additionally, postoperative pain negatively impacts the quality of life immediately after surgery. to lessen both the occurrence and intensity of post-surgical pain, numerous experts advocate for the use of multimodal therapy in surgical patients. the aim of this study was to evaluate the efficacy of combined low-pressure co2 pneumoperitoneum and intraperitoneal infusion of normal saline for reducing the incidence and severity of postoperative pain.


Eligibility criteria:
inclusion criteria: * patients who received vnotes hysterectomy and salpingectomy, with the option of additional procedures such as oophorectomy, uterosacral ligament plications, transobturator tape insertion, colporrhaphy, or sentinel lymphadenectomy. * asa status i-iii * voluntary participation exclusion criteria: * surgery time greater than 3 h, * suspected infection or malignancy or rectovaginal endometriosis * participation in other clinical trials. * presence of pre-surgical shoulder pain or any acute or chronic pain syndromes * cognitive impairment or communications disorder, * previous use of opioids for chronic pain,
safety and preliminary efficacy of sbrt in patients with metastatic rcc treated with targeted or io therapy

Conditions: Metastatic Renal Cell Carcinoma

Summary: aim of this phase 1b study is to evaluate safety and preliminary efficacy of stereotactic body radiation therapy in patients with metastatic renal cell carcinoma treated with vegfr, mtor or immune checkpoint inhibitors.

this is prospective phase 1b study. patients with metastatic rcc receiving targeted or io therapy (vegfr inhibitor or mtor inhibitor or checkpoint inhibitors in approved treatment lines and in standard therapeutic regimens) with stable diseaseor durable partial response for at least 4 months, are enrolled in the study. the initial examination includes ct with contrast, where the selected measured 2 metastatic sites, stable for at least 4 months but no more than 6 months of targeted therapy (increase or decrease in size in the course of targeted therapy should not exceed 10%). metastases have to be located in one organ. allowed location of metastases: lungs, liver, lymph nodes, contralateral kidney, adrenal gland. size of selected metastases should not be less than 5 mm and not more than 4 cm.

Eligibility criteria:
inclusion criteria: 1. clear cell renal cell carcinoma 2. confirmed distant metastases 3. previous nephrectomy 4. stable disease or durable partial response on recommended targeted and io therapy 5. age: \> 18 years 6. signed informed consent exclusion criteria: 1. unability to select first and second metastases 2. history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., new york heart association class iii or iv) 3. other malignancy 4. grade 3 and 4 toxicity of targeted therapy

Keywords: renal cell carcinoma metastasis stereotactic body radiation therapy targted therapy immune checkpoint inhibitors
study on the impact of ocular anesthetic procedures in ocular blood flow

Conditions: Open Angle Glaucoma

Summary: anaesthetic procedures in ophthalmology surgery have been a subject rapidly evolving in the past decades. when deciding for a retrobulbar block, the local injection of varying mixtures and volumes of fast-acting anesthetics (such as lidocaine) - with or without a vasoconstrictive agent (such as adrenaline) - coupled with hyaluronidase have been the standard care to provide painless surgery while minimizing the possible risks such as increased intraocular pressure (iop), brainstem anesthesia, toxic reaction and ocular blood flow changes. these iatrogenic-induced vascular dysfunctions have been also suggested to play a role in intra-operatory vision loss (a "wipe-out" phenomenon) in patients with advanced glaucoma. the rationale for the use of epinephrine in retrobulbar anesthesia is to slow absorption of the anesthetic in general circulation and thus to achieve a longer effect in the orbit. however, studies on ocular blood flow after adrenaline-containing compounds have consistently showed a decrease in ocular blood flow, thus raising the issue of whether it should be used in patients with known vascular dysfunction, namely glaucoma patients. nevertheless, there has been no study to verify this claim concerning the safety of non-adrenaline containing anesthetics. injecting a pre-determined volume of anesthetic compound behind the globe, regardless of its formulation has also been debated. the orbital pressure increase can lead to a number of adverse reactions, not only increasing iop but also potentially decreasing vascular input by local compression. in glaucoma for instance, there has been suggested optic nerve sheaths to be less elastic than in healthy individuals, potentially making this structure less compliant to outside compression. these more rigid orbital tissues could also impair the orbit's ability to deal with the iatrogenic increased volume. as seen, the current concepts on the impact of ocular anesthesiology in the orbit and the vascular supply to the eye are limited to a small number of non-homogeneous studies. we aim to study this impact through a non-invasive, widely established ultrasound based method of ocular blood flow research (color doppler imaging). potentially, our study could help determine a taylor-made choice of the anesthesiology procedure to apply to a specific patient, thereby advancing the current standard of care in ophthalmology.

1. ultrasound b-mode scans will be performed before and after the anesthetic procedure 2. doppler scan will be added to the b-mode ultrasound to register the blood flow pattern of the ophthalmic and central retinal arteries 3. blood pressure and heart rate will be monitored

Eligibility criteria:
inclusion criteria: * individuals over 18 years old * willing to sign an informed consent and able to comply with the requirements of the study exclusion criteria: * history of ocular trauma * previous extraocular surgery * ocular disease other than the one motivating surgery * systemic diseases with ocular involvement like diabetes or graves ophthalmopathy
efficacy of nasal oxygen therapy to reduce postoperative complications in ankle trauma surgery in at-risk patients: a randomized pilot study.

Conditions: Ankle Fractures

Summary: ankle fractures are one of the most common surgeries in the world. after this kind of surgery, complications can occur, related to the scar or an infection. these complications are more frequent in "high-risk" patients. nasal oxygen therapy is currently used in order to reduce these complications. however, no study proved its efficiency yet. in a cohort of 200 patients, one group will receive oxygen therapy during hospitalization, while the other will not. complication rates will be observed up to 6 months after the operation

prospective, single-center, comparative and randomized study based on a cohort of 200 patients with an ankle fracture. the patients will be assigned to one of the following group: with or without oxygen therapy. patients in the experimental group will receive the oxygen just before the operation, and during the hospitalization. the rest of the care is the same for the 2 groups. comparison of complication rate, of quality of healing, rate of revision surgery, delay in bone healing, rate of pseudoarthrosis, and ankle pain will be done between the 2 groups during a postoperative period of 6 months. a cost-utility analysis will also be realized. in a subgroup of 40 patients, additional transcutaneous oxygen pressure measurements will be performed to compare the evolution of tissue oxygenation between the 2 groups.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age * patient with an ankle joint injury with surgical indication * patient with at least one risk factor for scar complication such as comorbidity(ies) (diabetes, smoking, peripheral neuropathy, obstructive arterial disease of the lower limbs, microangiopathy, treatment influencing healing (chemotherapy, corticosteroids...)) and/or complex fracture * patient affiliated to a social security system * patient having signed an informed consent exclusion criteria: * patient with chronic respiratory insufficiency * patient with sleep apnea with equipment * patient under long term oxygen therapy * patient with a bilateral ankle fracture * polytrauma patients * pregnant or breastfeeding women or those refusing effective contraception * patient deprived of liberty or under legal protection (guardianship or curatorship) * patient unable to follow the protocol, as judged by the investigator * patient refusing to participate in the study